2014年美国临床肿瘤学会年会将于当地时间5月30日-6月3日在芝加哥召开，我国肿瘤专家江泽飞教授的一项研究被ASCO收录，下面和大家提前分享这项精彩研究。医脉通小编们今年也将继续奔赴ASCO年会现场，及时将各项最新研究进展整理、发布，欢迎大家保持关注！
应用过蒽环霉素+紫杉烷辅助或新辅助化疗的乳腺癌患者的百分比正逐渐增加，当患者乳腺癌转移时就会对这些药物产生抵抗。在靶向治疗时代，HER2阴性转移性乳腺癌的治疗仍需要联合化疗。吉西他滨+顺铂方案或长春瑞滨+顺铂方案可用于补救治疗。评估这两种治疗的效果和毒性作用是非常必要的。
研究方案
2005年4月至2013年5月间在乳腺癌研究中心治疗的186位以前应用过蒽环霉素+紫杉烷的转移性乳腺癌患者中，76位患者应用吉西他滨+顺铂(GP)方案，110位患者应用长春瑞滨+顺铂(NP)方案。每3周进行一疗程的化疗：第1天至第8天应用长春瑞滨25 mg/m2或吉西他滨1000 mg/m2，第1天时还应用顺铂75 mg/m2。
研究结果
应用GP方案的患者的客观缓解率为26.3%，应用NP方案的患者的客观缓解率为31.8%(P=0.419)。应用GP方案的患者的疾病稳定率为55.2%，应用NP方案的患者的疾病稳定率为54.5%。应用GP方案的患者的无进展生存期的中位数为5个月(95% CI: 3.8∼6.2个月)，应用NP方案的患者的无进展生存期的中位数为6个月(95% CI: 5.0∼6.9个月) (时序检验, P=0.797)。我们发现无进展生存期和客观缓解率的差异没有显著性。最常见的3-4级的不良反应是血液毒性（没有显著性差异）。两组中患者呕吐的发生率相似。
结论
该研究中我们观察到了相似的结果，两种包含顺铂的方案的疗效差异没有显著性。毒性反应也可以耐受。当然还需要长期的观察和进一步的分析。
医脉通整理报道，转载请注明出处。
会议专题》》》2014年ASCO年会专题报道
阅读英文摘要
Gemcitabine plus cisplatin versus vinorelbine plus cisplatin in patients with anthracycline- and taxane-pretreated HER2-negative metastatic breast cancer.（Abstract No:e12006）
Authors: Huiqiang Zhang, Tao Wang, Li Bian, Zefei Jiang，et al.
Background: The percentage of breast cancer patients exposed to anthracyclines and taxanes in the adjuvant or neoadjuvant chemotherapy is increasing, in metastatic stage using again is limited by drug resistance. In the targeted therapy era, the treatment of HER2-negative metastatic breast cancer (MBC) still need combination chemotherapy.Gemcitabine plus cisplatin and vinorelbine plus cisplatin have been used as salvage therapy. It is necessary to evaluate the efficacy and toxicity of the two treatments.
Methods: We conducted this study. 186 patients with metastatic breast cancer pretreated with anthracyclines and taxanes received gemcitabine-cisplatin (GP) (n=76) and ,vinorelbine-cisplatin (NP) (n=110), at The Department of Breast Cancer between 2005.04 and 2013.05. Chemotherapy was given every 3 weeks as follows: vinorelbine (25 mg/m2) or gemcitabine (1000mg/m2) all on day 1–day 8; and cisplatin (75 mg/m2) on day 1 every 3 weeks.
Results: The objective response rate (ORR) to GP was 26.3% and to NP 31.8% (P=0.419). Disease stabilized is 55.2% and 54.5% of patients treated with GP and NP respectively. Median progression-free survival (PFS) for the GP and NP groups was 5 months (95% CI: 3.8∼6.2 months) and 6 months (95% CI: 5.0∼6.9 months) (log-rank, P=0.797). We observed no difference of PFS and ORR. The main adverse events of grade 3~4 were hematological toxicities without statistical significance. The incidence rate of vomiting was similar in GP and NP groups.
Conclusions: We had observed the similar results in this study, the efficacy of two cisplatin-based regimens had no difference. And toxicity was acceptable. Longer observation and further analysis are warranted.
